Shanghai Junshi Bioscience Co., Ltd.

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. The study included 531 participants and compared…

This Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, mea…

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but r…

This phase 3 trial tested whether combining the immunotherapy toripalimab with the targeted drug axitinib works better than the standard drug sunitinib for people with advanced kidney cancer that cannot be removed by surgery. Over 400 participants received either the combination …

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with recurrent or metastatic nasopharyngeal cancer live longer without their disease getting worse. About 289 adults with advanced cancer that could not be treated wi…

This study tested whether two different injection devices (a pre-filled syringe and an automatic injector) deliver the same amount of the drug JS005 into the body. It involved 272 healthy adults who received a single injection and were followed for 85 days. The goal was to see if…